{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:25:53Z","timestamp":1788042353147,"version":"build-2784847793"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["101007939"],"award-info":[{"award-number":["101007939"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejpb.2024.114387","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:38:19Z","timestamp":1719513499000},"page":"114387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Light exacerbates local and global effects induced by pH unfolding of Ipilimumab"],"prefix":"10.1016","volume":"201","author":[{"given":"Elena","family":"Rizzotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Inciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fongaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Trolese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Miolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Polverino de Laureto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114387_b0005","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2024.114387_b0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: The basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (basel)"},{"key":"10.1016\/j.ejpb.2024.114387_b0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1146\/annurev.iy.01.040183.000511","article-title":"Structural basis of antibody function","volume":"1","author":"Davies","year":"1983","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejpb.2024.114387_b0020","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/bit.23155","article-title":"Aggregates in monoclonal antibody manufacturing processes","volume":"108","author":"V\u00e1zquez-Rey","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejpb.2024.114387_b0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/02648725.2001.10648017","article-title":"Industrial purification of pharmaceutical antibodies: Development, operation, and validation of chromatography processes","volume":"18","author":"Fahrner","year":"2001","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"10.1016\/j.ejpb.2024.114387_b0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chroma.2015.08.068","article-title":"Protein A chromatography increases monoclonal antibody aggregation rate during subsequent low pH virus inactivation hold","volume":"1415","author":"Mazzer","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejpb.2024.114387_b0035","first-page":"3188","article-title":"Mimicking low pH virus inactivation used in antibody manufacturing processes: Effect of processing conditions and biophysical properties on antibody aggregation and particle formation","volume":"110","author":"Kim","year":"2021","journal-title":"JPharmSci"},{"key":"10.1016\/j.ejpb.2024.114387_b0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jchromb.2006.09.026","article-title":"Downstream processing of monoclonal antibodies\u2014Application of platform approaches","volume":"848","author":"Shukla","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2024.114387_b0045","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1096\/fasebj.10.1.8566531","article-title":"The roles of partly folded intermediates in protein folding","volume":"10","author":"Creighton","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/j.ejpb.2024.114387_b0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: Potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114387_b0055","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibs.2004.03.009","article-title":"The antibody-catalyzed water oxidation pathway \u2013 a new chemical arm to immune defense?","volume":"29","author":"Nieva","year":"2004","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.ejpb.2024.114387_b0060","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejpb.2022.05.005","article-title":"Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions","volume":"176","author":"Fongaro","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2024.114387_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejpb.2024.114387_b0070","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/pro.2340","article-title":"Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress","volume":"22","author":"Ito","year":"2013","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejpb.2024.114387_b0075","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11095-012-0885-3","article-title":"Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: From oligomers to larger aggregates","volume":"30","author":"Arosio","year":"2013","journal-title":"Pharm Res"},{"key":"10.1016\/j.ejpb.2024.114387_b0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jchromb.2017.09.033","article-title":"Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies","volume":"1065\u20131066","author":"Goyon","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2024.114387_b0085","first-page":"5","article-title":"CTLA-4 blockade in tumor models: an overview of preclinical and translational research","volume":"13","author":"Grosso","year":"2013","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ejpb.2024.114387_b0090","doi-asserted-by":"crossref","first-page":"E4223","DOI":"10.1073\/pnas.1617941114","article-title":"Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab","volume":"114","author":"Ramagopal","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2024.114387_b0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejpb.2015.12.003","article-title":"Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development","volume":"100","author":"Sreedhara","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ejpb.2024.114387_b0100","doi-asserted-by":"crossref","first-page":"9328","DOI":"10.1021\/bi100841u","article-title":"Acid-induced aggregation of human monoclonal IgG1 and IgG2: Molecular mechanism and the effect of solution composition","volume":"49","author":"Hari","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2024.114387_b0105","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bit.27237","article-title":"Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization","volume":"117","author":"W\u00e4lchli","year":"2020","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.ejpb.2024.114387_b0110","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1021\/bi00303a044","article-title":"Determination of tyrosine exposure in proteins by second-derivative spectroscopy","volume":"23","author":"Ragone","year":"1984","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejpb.2024.114387_b0115","series-title":"Advances in Enzymology and Related Areas of Molecular Biology","first-page":"401","article-title":"The Specificity and Mechanism of Pepsin Action","author":"Fruton","year":"1970"},{"key":"10.1016\/j.ejpb.2024.114387_b0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1432-1033.1974.tb03671.x","article-title":"Proteinase K from tritirachium album limber","volume":"47","author":"Ebeling","year":"1974","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.ejpb.2024.114387_b0125","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2024.114387_b0130","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1110\/ps.0205802","article-title":"Partly folded states of members of the lysozyme\/lactalbumin superfamily: A comparative study by circular dichroism spectroscopy and limited proteolysis","volume":"11","author":"Polverino de Laureto","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejpb.2024.114387_b0135","series-title":"Proteolytic Enzymes","first-page":"253","article-title":"Limited proteolysis in the study of protein conformation","author":"Fontana","year":"1999"},{"key":"10.1016\/j.ejpb.2024.114387_b0140","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1042\/bj2370899","article-title":"A systematic series of synthetic chromophoric substrates for aspartic proteinases","volume":"237","author":"Dunn","year":"1986","journal-title":"Biochem. J"},{"key":"10.1016\/j.ejpb.2024.114387_b0145","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0165-022X(00)00141-X","article-title":"Pepsin digestion of a mouse monoclonal antibody of IgG1 class formed F(ab\u2032)2 fragments in which the light chains as well as the heavy chains were truncated","volume":"48","author":"Inouye","year":"2001","journal-title":"J. Biochem. Bioph. Methods"},{"key":"10.1016\/j.ejpb.2024.114387_b0150","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1021\/ja0705994","article-title":"\u03b2-elimination and peptide bond hydrolysis: Two distinct mechanisms of human IgG1 hinge fragmentation upon storage","volume":"129","author":"Cohen","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejpb.2024.114387_b0155","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00726-019-02787-2","article-title":"Susceptibility of protein therapeutics to spontaneous chemical modifications by oxidation, cyclization, and elimination reactions","volume":"51","author":"Grassi","year":"2019","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejpb.2024.114387_b0160","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1039\/D1OB00411E","article-title":"Approaches for peptide and protein cyclisation","volume":"19","author":"Hayes","year":"2021","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejpb.2024.114387_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.ejpb.2024.114387_b0170","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/prot.21243","article-title":"Effects of acid exposure on the conformation, stability, and aggregation of monoclonal antibodies, Proteins: Structure","volume":"66","author":"Ejima","year":"2007","journal-title":"Function, and Bioinformatics"},{"key":"10.1016\/j.ejpb.2024.114387_b0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1039\/c1pp05164d","article-title":"Photo-oxidation of proteins","volume":"11","author":"Pattison","year":"2011","journal-title":"Photochem. Photobiol. Sci."},{"key":"10.1016\/j.ejpb.2024.114387_b0180","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1096\/fasebj.6.8.1592207","article-title":"Protein folding and protein refolding","volume":"6","author":"Seckler","year":"1992","journal-title":"FASEB J"},{"key":"10.1016\/j.ejpb.2024.114387_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2020.107764","article-title":"Understanding unfolding and refolding of the antibody fragment (Fab). I. In-vitro study","volume":"164","author":"Gani","year":"2020","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.ejpb.2024.114387_b0190","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.csbj.2020.03.002","article-title":"Modelling of pH-dependence to develop a strategy for stabilising mAbs at acidic steps in production","volume":"18","author":"Hebditch","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejpb.2024.114387_b0195","first-page":"4587","article-title":"Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid\u2013liquid phase separation","volume":"100","author":"Mason","year":"2011","journal-title":"JPharmSci"},{"key":"10.1016\/j.ejpb.2024.114387_b0200","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","article-title":"Fragmentation of monoclonal antibodies","volume":"3","author":"Vlasak","year":"2011","journal-title":"Mabs"},{"key":"10.1016\/j.ejpb.2024.114387_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123926","article-title":"Towards a better understanding of light-glucose induced modifications on the structure and biological activity of formulated Nivolumab","volume":"654","author":"De Diana","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114387_b0210","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3389\/fimmu.2020.00725","article-title":"Immunogenicity of bioproducts: cellular models to evaluate the impact of therapeutic antibody aggregates","volume":"11","author":"Nabhan","year":"2020","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1016\/j.ejpb.2024.114421","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124002133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T13:54:10Z","timestamp":1729173250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124002133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"alternative-id":["S0939641124002133"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114387","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejpb.2024.114421","asserted-by":"object"}]},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Light exacerbates local and global effects induced by pH unfolding of Ipilimumab","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114387"}}